These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26636371)

  • 1. Energy-Based Pharmacophore and Three-Dimensional Quantitative Structure--Activity Relationship (3D-QSAR) Modeling Combined with Virtual Screening To Identify Novel Small-Molecule Inhibitors of Silent Mating-Type Information Regulation 2 Homologue 1 (SIRT1).
    Pulla VK; Sriram DS; Viswanadha S; Sriram D; Yogeeswari P
    J Chem Inf Model; 2016 Jan; 56(1):173-87. PubMed ID: 26636371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
    Panathur N; Dalimba U; Koushik PV; Alvala M; Yogeeswari P; Sriram D; Kumar V
    Eur J Med Chem; 2013 Nov; 69():125-38. PubMed ID: 24013412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence.
    Scisciola L; Sarno F; Carafa V; Cosconati S; Di Maro S; Ciuffreda L; De Angelis A; Stiuso P; Feoli A; Sbardella G; Altucci L; Nebbioso A
    Epigenetics; 2020; 15(6-7):664-683. PubMed ID: 31942817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated Ligand and Structure-Based Investigation of Structural Requirements for Silent Information Regulator 1 (SIRT1) Activation.
    Gupta AK; Choi S
    Curr Top Med Chem; 2018; 18(27):2313-2324. PubMed ID: 30569858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand efficiency based approach for efficient virtual screening of compound libraries.
    Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
    Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
    Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
    Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents.
    Patel P; Singh A; Patel VK; Jain DK; Veerasamy R; Rajak H
    Comb Chem High Throughput Screen; 2016; 19(9):735-751. PubMed ID: 27487787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies.
    Mellini P; Carafa V; Di Rienzo B; Rotili D; De Vita D; Cirilli R; Gallinella B; Provvisiero DP; Di Maro S; Novellino E; Altucci L; Mai A
    ChemMedChem; 2012 Nov; 7(11):1905-8. PubMed ID: 24155041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of highly potent TNFα inhibitors using virtual screen.
    Shen Q; Chen J; Wang Q; Deng X; Liu Y; Lai L
    Eur J Med Chem; 2014 Oct; 85():119-26. PubMed ID: 25078315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
    Choubey SK; Jeyaraman J
    J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
    Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
    J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders.
    Pulla VK; Alvala M; Sriram DS; Viswanadha S; Sriram D; Yogeeswari P
    J Mol Graph Model; 2014 Jul; 52():46-56. PubMed ID: 25000096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of QSAR and shape pharmacophore modeling approaches for targeted chemical library design.
    Ebalunode JO; Zheng W; Tropsha A
    Methods Mol Biol; 2011; 685():111-33. PubMed ID: 20981521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
    Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
    Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
    Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
    Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.